## **Andrew Tom Bates**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4476761/publications.pdf

Version: 2024-02-01

1162889 1474057 9 476 8 9 citations g-index h-index papers 9 9 9 959 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Breast Cancer Risk After Supradiaphragmatic Radiotherapy for Hodgkin's Lymphoma in England and Wales: A National Cohort Study. Journal of Clinical Oncology, 2012, 30, 2745-2752.	0.8	142
2	Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases. Journal of the National Cancer Institute, 2014, 106, .	3.0	105
3	Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer. JAMA - Journal of the American Medical Association, 2019, 322, 2084.	3.8	71
4	Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. BMJ Open, 2018, 8, e020690.	0.8	56
5	Risk of Premature Menopause After Treatment for Hodgkin's Lymphoma. Journal of the National Cancer Institute, 2014, 106, .	3.0	48
6	PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy. International Journal of Radiation Oncology Biology Physics, 2005, 62, 148-153.	0.4	19
7	Variation in geographical treatment intensity affects survival of non-small cell lung cancer patients in England. Cancer Epidemiology, 2018, 57, 13-23.	0.8	18
8	Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5â€year results from a <scp>UK</scp> National Cancer Research Institute Lymphoma Group study. British Journal of Haematology, 2016, 173, 274-282.	1.2	12
9	Fractionated 90y Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy As An Initial Therapy of Follicular Lymphoma – First Results From a Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. Blood, 2011, 118, 102-102.	0.6	5